The present invention aims to provide an aqueous adhesive which has both good moldability and strong adhesive force to the skin, and provides good feeling when used. The present invention can provide an adhesive with good shape retention performance by formulating two or more aqueous macromolecules, polyhydric alcohols, aqueous and insoluble cross-linking agents.

The invention is to provide a hydrogen sulfide sustained releasing dressing and a manufacturing method thereof. The hydrogen sulfide sustained releasing dressing includes a hydrocolloid, a surfactant and sodium hydro sulfide. The manufacturing method includes (a) heating and stirring a hydrocolloid material; (b) adding a surfactant and sodium hydrosulfide into the hydrocolloid material; and (c) injecting the hydrocolloid material containing the surfactant and the sodium hydrosulfide into a mold for thermoforming a hydrogen sulfide sustained releasing dressing.

Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.

The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.

The present disclosure relates to the transdermal administration of pharmaceutical agents, such as CBD, THC, psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment and/or prevention and/or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

A ropinirole-containing patch comprising an adhesive agent layer and a backing layer, wherein the adhesive agent layer containing: at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof; a fatty acid metal salt having 7 or more carbon atoms; and an adhesive agent.

Provided herein are compositions, delivery devices, and methods relating to the delivery of tetrabenazine and/or deuterated tetrabenazine, for example, continuous or substantially continuous delivery such as transdermal delivery, for the treatment of a hyperkinetic movement disorder. Also provided are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, pharmaceutical compositions comprising tetrabenazine and/or a deuterated tetrabenazine, methods of preparing the same, and methods of using the same for example, for the treatment of a hyperkinetic movement disorder.

The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.